Adeline Siew, PhD

Experts discuss factors affecting drug delivery to the lungs and key considerations when developing inhalation formulations.

Pharmaceutical companies are using formulation strategies as a lifecycle management tool to maximize product value and preserve their revenue streams.

Mass detection at the push of a button could change the way many laboratories carry out their chromatographic analysis.

The Parenteral Drug Association has established a task force to develop a peer- and regulatory agency-reviewed Technical Report that will serve as a science-based industry reference document.

An updated bioreactor based on rocking technology has more advanced controls but is easier for biopharmaceutical manufacturers to use.

PharmTech spoke with Dow about innovations in polymers to address poor solubility.

The success of Adcetris and Kadcyla is paving the way for more antibody drug conjugates to enter the market, especially in the treatment of solid tumors.

Formulation and process considerations for ethyl cellulose aqueous dispersion in sustained-release applications.

Industry experts discuss the importance of characterization studies during biosimilars development and related analytical methods.

Scientists from the CDMO Metrics talk about the challenges in developing oral formulations for poorly permeable drugs and the strategies used to enhance oral absorption in the gastrointestinal tract.

Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.

The new subcutaneous formulation of Herceptin can be administered six times faster than the standard intravenous formulation.

FDA has issued a safety alert after a patient with multiple sclerosis in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy following treatment with Gilenya (fingolimod).

Industry experts discuss the requirements and challenges involved in getting a biosimilar product from bench to launch.

Mike Jenkins, general manager of Catalent Biologics discusses the evolving landscape of the biologics market and hurdles faced in the development and manufacture of these innovative products.

The MHRA has issued a warning to the public not to use unlicensed traditional Chinese medicines after discovering that some of them contain dangerously high levels of lead, mercury and arsenic.

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China.

ABPI toolkit provides guidance to pharmaceutical companies on how to meet clinical trial transparency requirements

Rx-360, a pharmaceutical industry supply-chain consortium, is advancing approaches between pharmaceutical companies, suppliers, and contract manufacturers to better secure the pharmaceutical supply chain.

Industry groups offered perspectives on the strengths and weaknesses of the European Falsified Medicines Directive.

Scientists at A*STAR's Genome Institute of Singapore (GIS) have identified genes that could be potential targets for anticancer agents in the treatment of aggressive breast cancer.

Adaptimmune has opened a Phase I/IIa ovarian cancer trial to evaluate its genetically engineered T cell treatment, with enhanced antitumor activity.

The report highlights a need for greater third party certification to ensure GMP vigilance.

Molecular Profiles has opened a new facility in the UK following official approval from MHRA.

The new ink takes less a second to dry and is four times more fade resistant than inks that are typically used in retail packaging.

Almac introduces handling and bottling capabilities in EU and US headquarters.

Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.

Osmotic systems offer versatility for delivering drugs with varied properties and dosage requirements.

Entries open to any company across three categories - formulation, process development and best packaging.

Lundbeck and eight other pharmaceutical companies have been fined for delaying generic entry of the blockbuster antidepressant, Celexa (citalopram), into the market.